Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR8 | P51685 | 8/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 8/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 11/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | USP2 | O75604 | 4/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2076736 | 0.85 | CCR8 (0.74) | CCR8KCNH2CYP2D6TSHR | |
| SCHEMBL4238747 | 0.85 | CCR8 (0.73) | CCR8KCNH2CYP2D6TSHRUSP2 | |
| SCHEMBL5247234 | 0.85 | CCR8 (0.73) | CCR8KCNH2CYP2D6TSHRUSP2 | |
| SCHEMBL2077637 | 0.84 | CCR8 (0.73) | CCR8KCNH2CYP2D6TSHRUSP2 | |
| SCHEMBL4234222 | 0.84 | CCR8 (0.72) | CCR8KCNH2CYP2D6TSHRUSP2 | |
| SCHEMBL5255658 | 0.84 | CCR8 (0.72) | CCR8KCNH2CYP2D6TSHRUSP2 | |
| SCHEMBL2074540 | 0.83 | CCR8 (0.71) | CCR8KCNH2CYP2D6TSHRUSP2 | |
| SCHEMBL5196417 | 0.81 | CCR8 (0.75) | CCR8KCNH2CYP2D6TSHRUSP2 | |
| SCHEMBL5229766 | 0.81 | CCR8 (0.74) | CCR8KCNH2CYP2D6TSHRUSP2 | |
| SCHEMBL2074557 | 0.80 | CCR8 (0.67) | CCR8KCNH2CYP2D6TSHRUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053969-A1 | NOVEL DIAZASIPIROAKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2011-03-03 | — | — | US | claimed |
| US-20110053969-A1 | NOVEL DIAZASIPIROAKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2011-03-03 | — | — | US | disclosed |
| US-20110053969-A1 | NOVEL DIAZASIPIROAKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2011-03-03 | — | — | US | disclosed |
| US-20110053969-A1 | NOVEL DIAZASIPIROAKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2011-03-03 | — | — | US | disclosed |
| EP-1869045-A1 | NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES | AstraZeneca AB (SE) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006107254-A1 | NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053969-A1 | NOVEL DIAZASIPIROAKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES | CCR8, CCR1, CCR3 | CCR8 1/4885KCNH2 3558/4885CYP2D6 1200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.